ArticleJournal of clinical microbiology2008
Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents.
Article in Journal of clinical microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 128 citations in OpenAlex.
- Dynamics of 1,3-β-D-Glucan in Invasive Candidiasis: A Narrative Review of Microbiological Aspects and Diagnostic Implications.Antibodies (Basel, Switzerland) · 2026Review
- Article
- An update on clinically relevant, rare, and emergingClinical microbiology reviews · 2025Review
- Article
- Variations in virulence factors, antifungal susceptibility and extracellular polymeric substance compositions of cryptic and uncommon Candida species from oral candidiasis.BMC oral health · 2025Article
- Article
- Review
- Molecular Epidemiology and Antifungal Susceptibility Profile in Nakaseomyces glabrata Species Complex: A 5-Year Countrywide Study.Journal of clinical laboratory analysis · 2024Article
- Three cases of vulvovaginal candidiasis due toMedical mycology case reports · 2024Article
- Enhancing ascitic fungal infection diagnosis through next-generation sequencing: a pilot study in surgical ICU patients.Frontiers in cellular and infection microbiology · 2024Article
- Changes in fungal taxonomy: mycological rationale and clinical implications.Clinical microbiology reviews · 2023Review
- Article
- Candidiasis byJournal of fungi (Basel, Switzerland) · 2021Article
- Review
- Species Distribution, Antifungal Susceptibility, and Molecular Epidemiology ofJournal of fungi (Basel, Switzerland) · 2021Article
- Challenges and Opportunities in Understanding Genetics of Fungal Diseases: Towards a Functional Genomics Approach.Infection and immunity · 2021Review
- Genome and transcriptome of a pathogenic yeast, Candida nivariensis.G3 (Bethesda, Md.) · 2021Article
- Molecular Markers of Antifungal Resistance: Potential Uses in Routine Practice and Future Perspectives.Journal of fungi (Basel, Switzerland) · 2021Review
- First Isolation of Candida nivariensis, an Emerging Fungal Pathogen, in Kuwait.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Article
- Caenorhabditis elegans as a Model System To Assess Candida glabrata,Antimicrobial agents and chemotherapy · 2020Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2005, Candida nivariensis, a yeast species genetically related to Candida glabrata, was described following its isolation from three patients in a single Spanish hospital. Between 2005 and 2006, 16 fungal isolates with phenotypic similarities to C. nivariensis were submitted to the United Kingdom Mycology Reference Laboratory for identification. The strains originated from various clinical specimens, including deep, usually sterile sites, from patients at 12 different hospitals in the United Kingdom. PCR amplification and sequencing of the D1D2 and internal transcribed spacer 1 (ITS1) regions of the nuclear ribosomal gene cassette confirmed that these isolates from the United Kingdom are genetically identical to C. nivariensis. Biochemically, C. glabrata and C. nivariensis are distinguished by their differential abilities to assimilate trehalose. However, in contrast to the original published findings, we found that C. glabrata isolates, but not C. nivariensis isolates, are capable of assimilating this substrate. Antifungal susceptibility tests revealed that C. nivariensis isolates are less susceptible than C. glabrata isolates to itraconazole, fluconazole, and voriconazole and to have significantly higher flucytosine MICs than C. glabrata strains. Finally, C. nivariensis could be rapidly distinguished from the other common pathogenic fungus species by pyrosequencing of the ITS2 region. In the light of these data, we believe that C. nivariensis should be regarded as a clinically important emerging pathogenic fungus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.